{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T18:43:32Z","timestamp":1776883412280,"version":"3.51.2"},"reference-count":28,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics and Practice"],"abstract":"<jats:p>Background\/Objectives: Alopecia areata (AA) and psoriasis are immune-mediated diseases that can coexist, suggesting shared pathogenic mechanisms. While Janus kinase inhibitors (JAKi) are approved for AA treatment, their role in managing concomitant psoriasis and psoriatic arthritis (PsA) remains unclear. This study evaluates the efficacy and safety of baricitinib in patients with severe AA and coexisting psoriasis and\/or PsA. Materials and Methods: A retrospective case series of five patients (mean age 53.2 years) with severe AA (SALT &gt; 80) or alopecia universalis (AU) and concomitant psoriasis (n = 2) and\/or PsA (n = 3) was conducted in the Dermatology Unit of Policlinico of Tor Vergata, Catholic University of the Sacred Heart and La Sapienza University of Rome, Italy. Patients received baricitinib 4 mg\/day and were assessed at weeks 4, 24, and 52 using SALT, PASI, and pVAS scores. Results: At week 52, one patient achieved complete AA remission, while two improved to SALT &lt; 20 (mean SALT 83 to 8.75). Psoriasis remained stable (mean PASI 1.4 to 0.5). However, one PsA patient worsened (pVAS 9) and discontinued the treatment. Conclusions: Baricitinib was effective for AA, with potential benefits for psoriasis, but it may not be optimal for PsA. Further studies are needed to define its role in multiple immune diseases.<\/jats:p>","DOI":"10.3390\/clinpract16020028","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:56:12Z","timestamp":1769615772000},"page":"28","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy"],"prefix":"10.3390","volume":"16","author":[{"given":"Enrico","family":"Matteini","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00134 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-3532","authenticated-orcid":false,"given":"Fabio","family":"Artosi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00134 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-9232","authenticated-orcid":false,"given":"Giacomo","family":"Caldarola","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario \u201cA. Gemelli\u201d\u2014IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1746-2708","authenticated-orcid":false,"given":"Lorenzo Maria","family":"Pinto","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario \u201cA. Gemelli\u201d\u2014IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Rossi","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia, \u201cSapienza\u201d University of Rome, 00185 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3843-420X","authenticated-orcid":false,"given":"Lorenzo","family":"Ala","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia, \u201cSapienza\u201d University of Rome, 00185 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1115-4270","authenticated-orcid":false,"given":"Gaetana","family":"Costanza","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome \u201cTor Vergata\u201d, 00134 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-6896","authenticated-orcid":false,"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00134 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7447-6798","authenticated-orcid":false,"given":"Elena","family":"Campione","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00134 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1844-9052","authenticated-orcid":false,"given":"Laura","family":"Diluvio","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00134 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"104820","DOI":"10.1016\/j.amsu.2022.104820","article-title":"Two-way association between alopecia areata and sleep disorders: A systematic review of observational studies","volume":"84","author":"Rehan","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.1111\/jdv.19663","article-title":"Effect of baricitinib in patients with alopecia areata: Usefulness of trichoscopic evaluation","volume":"38","author":"Diluvio","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijwd.2017.07.001","article-title":"Quality of life in mild and severe alopecia areata patients","volume":"4","author":"Abedini","year":"2017","journal-title":"Int. J. Womens Dermatol."},{"key":"ref_4","unstructured":"World Health Organization (2016). Global Report on Psoriasis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40744-019-0159-1","article-title":"Psoriatic Arthritis: What is Happening at the Joint?","volume":"6","author":"Belasco","year":"2019","journal-title":"Rheumatol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/1346-8138.16420","article-title":"Association between psoriasis and alopecia areata: A systematic review and meta-analysis","volume":"49","author":"Jung","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_10","first-page":"E9","article-title":"Recovery of hair in the psoriatic plaques of a patient with coexistent alopecia universalis","volume":"99","author":"Anastasiou","year":"2017","journal-title":"Cutis"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing","volume":"136","author":"Ungar","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.it.2011.06.007","article-title":"T helper 17 cell heterogeneity and pathogenicity in autoimmune disease","volume":"32","author":"Ghoreschi","year":"2011","journal-title":"Trends Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two Phase 3 Trials of Baricitinib for Alopecia Areata","volume":"18","author":"King","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40265-023-01873-w","article-title":"Baricitinib for the Treatment of Alopecia Areata","volume":"83","author":"Freitas","year":"2023","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1111\/jdv.18263","article-title":"The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis\u2014A network meta-analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1177\/12034754221141680","article-title":"Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway","volume":"27","author":"Loo","year":"2023","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/1744666X.2023.2299732","article-title":"Upadacitinib for the treatment of adult patients with active psoriatic arthritis","volume":"20","author":"Marchesoni","year":"2024","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_21","first-page":"e391","article-title":"Baricitinib-induced paradoxical psoriasis","volume":"34","author":"Castagna","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13555-022-00711-3","article-title":"Defining Severity in Alopecia Areata: Current Perspectives and a Multidimensional Framework","volume":"12","author":"King","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cei\/uxac088","article-title":"Stratification of alopecia areata reveals involvement of CD4 T cell populations and altered faecal microbiota","volume":"210","author":"Bain","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Liu, T., Li, S., Ying, S., Tang, S., Ding, Y., Li, Y., Qiao, J., and Fang, H. (2020). The IL-23\/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.594735"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000508782","article-title":"Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis During Treatment with Tofacitinib: A Case Report","volume":"12","author":"Todberg","year":"2020","journal-title":"Case Rep. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13555-023-00889-0","article-title":"Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib\u2014A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata","volume":"13","author":"Reich","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(23)00921-2","article-title":"Baricitinib in juvenile idiopathic arthritis: An international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial","volume":"402","author":"Ramanan","year":"2023","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.2147\/JIR.S356316","article-title":"Application of Baricitinib in Dermatology","volume":"15","author":"Zhang","year":"2022","journal-title":"J. Inflamm. Res."}],"container-title":["Clinics and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2039-7283\/16\/2\/28\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:30:37Z","timestamp":1769617837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-7283\/16\/2\/28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["clinpract16020028"],"URL":"https:\/\/doi.org\/10.3390\/clinpract16020028","relation":{},"ISSN":["2039-7283"],"issn-type":[{"value":"2039-7283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}